PinnyPeptide

SS-31 (Elamipretide) vs Vesugen

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

SS-31 (Elamipretide)

Longevity

Mitochondria-targeted tetrapeptide that restores bioenergetics by stabilizing cardiolipin.

Peptide B

Vesugen

Bioregulators

Khavinson short peptide bioregulator targeting vascular endothelium — KED tripeptide.

Typical vial

5 mg

Typical dose

5000-50000 mcg

Half-life

~4 hours

FDA status

Not FDA approved. FDA declined approval for Barth syndrome i…

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

SS-31 (Elamipretide) effects

  • Stabilizes cardiolipin at the mitochondrial inner membrane
  • Restores electron transport chain efficiency and ATP production
  • Reduces mitochondrial ROS production at the source
  • Protects against ischemia-reperfusion injury in heart and kidney
  • Improves age-related mitochondrial dysfunction

Vesugen effects

  • Reported improvement in endothelial function (flow-mediated dilation)
  • Reduction in arterial stiffness measures
  • Anti-inflammatory effects on vascular endothelium
  • Modulation of vascular gene expression
  • Support of nitric oxide synthesis

SS-31 (Elamipretide) side effects

  • Injection site reactions (pain, redness)
  • Mild headache
  • Transient flushing
  • Occasional dizziness

Vesugen side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation
  • Should not substitute for proven cardiovascular therapies

SS-31 (Elamipretide) dosing ranges

Mitochondrial support and longevity

5-50 mg · Once daily (SubQ) · 4-12 weeks

Vesugen dosing ranges

Vascular health support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Full SS-31 (Elamipretide) guide → Full Vesugen guide →

SS-31 (Elamipretide) vs Vesugen — common questions

What is the difference between SS-31 (Elamipretide) and Vesugen?

SS-31 (Elamipretide): Mitochondria-targeted tetrapeptide that restores bioenergetics by stabilizing cardiolipin. Typical dose 5000-50000 mcg. Vesugen: Khavinson short peptide bioregulator targeting vascular endothelium — KED tripeptide. Typical dose 1,000-5,000 mcg. Both fall under the Longevity and Bioregulators categories.

Can you stack SS-31 (Elamipretide) and Vesugen?

Stacking SS-31 (Elamipretide) with Vesugen is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, SS-31 (Elamipretide) or Vesugen?

SS-31 (Elamipretide) is typically dosed: Once daily (SubQ) for Mitochondrial support and longevity. Vesugen is typically dosed: Once daily (SubQ) or sublingual for Vascular health support.

Are SS-31 (Elamipretide) and Vesugen FDA approved?

SS-31 (Elamipretide): Not FDA approved. FDA declined approval for Barth syndrome in 2023, requesting additional efficacy data. Multiple clinical trials ongoing for other mitochondrial indications. Vesugen: Not FDA approved.

Related peptide comparisons

epithalon vs ss-31fox04-dri vs ss-31mots-c vs ss-31n-acetyl-epitalon vs ss-31nad-plus vs ss-31pinealon vs ss-31

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free